Alzheimer’s Disease: detection, diagnosis, treatment

It is estimated that over 7 million people are living with Alzheimer's Disease in Europe, and there is increasing concern about the ability to combat the disease with Europe's ageing population.

In this series of articles, Euractiv will explore the state of play with Alzheimer's Disease, focusing on improving the tools and healthcare infrastructure as it relates to detection, diagnosis and treatment of the disease.

• Alzheimer’s drug lecanemab, EMA re-examining marketing authorisation

  News | Advocacy Lab Content | Health 01-10-2024

  Est. 6min
  

  The European Medicines Agency’s human medicines committee is re-examining the marketing authorisation application for the Alzheimer’s disease (AD) drug lecanemab, a treatment that has been shown to slow cognitive decline.

• EU needs Alzheimer’s plan with concrete measures and deadlines, says EPP’s SANT coordinator

  News | Advocacy Lab Content | Health 26-07-2024

  Est. 5min
  

  Europe needs a plan to address Alzheimer’s Disease that contains concrete measures, each with its own deadlines, and supported with proper funding, MEP Tomislav Sokol (EPP) told Euractiv.

• Progress on Alzheimer’s Disease stagnating, warns federation chief

  News | Advocacy Lab Content | Health 04-06-2024

  Est. 5min
  

  Progress on Alzheimer’s Disease and dementia is stagnating, Alzheimer Disease International CEO Paola Barbarino has warned, yet it’s the most common form of dementia in Europe's elderly.

Health

Alzheimer’s drug lecanemab, EMA re-examining marketing authorisation

01/10/2024

5 min. read

Health

EU needs Alzheimer’s plan with concrete measures and deadlines, says EPP’s SANT coordinator

26/07/2024

4 min. read

Health

Progress on Alzheimer’s Disease stagnating, warns federation chief

04/06/2024

5 min. read